Compositions and methods for the prevention of microbial infections

Patent metadata

Field	Value
Publication number	US-9745366-B2
Application number	US-201414493051-A
Country	US
Kind code	B2
Filing date	Sep 22, 2014
Priority date	Sep 23, 2013
Publication date	Aug 29, 2017
Grant date	Aug 29, 2017

Abstract

This disclosure provides methods and compositions to inhibit or prevent infection of a cell by a bacteria that exports DNABII proteins by administering to a tissue infected with the bacteria an effective amount of an antibody that specifically recognizes and binds the DNABII proteins, thereby inhibiting or preventing infection of the bacteria. Treatment methods, screens and kits are further provided.

First claim

What is claimed is:

1. A method to inhibit or prevent infection of a cell by a bacteria that exports a DNABII protein, comprising administering to a tissue comprising the cell an antibody that specifically recognizes and binds the DNABII protein or an antibody fragment that specifically recognizes and binds the DNABII protein, in an amount effective to inhibit or prevent infection of the cell by the bacteria that exports the DNABII protein.

2. The method of claim 1 , further comprising administering an effective amount of an additional antibacterial agent that is not the antibody that inhibits the growth of the bacteria or infection by the bacteria.

3. The method of claim 2 , wherein the antibacterial agent is an antibiotic.

4. The method of any one of claim 1 , 2 , or 3 , wherein the administering is in vitro or in vivo.

5. A method to treat a bacterial infection in a subject in need thereof, wherein the bacteria causing the infection exports a DNABII protein and wherein the subject is infected with the bacteria, the method comprising administering to the subject an antibody that specifically recognizes and binds the DNABII protein or an antibody fragment that specifically recognizes and binds the DNABII protein, in an amount effective to treat the bacterial infection in the subject.

6. The method of any one of claim 1 or 5 , wherein the effective amount of antibody or an antibody fragment that specifically recognizes and binds the DNABII protein, is delivered in a microsphere or by coating an in situ device with the antibody an antibody fragment that specifically recognizes and binds the DNABII protein.

7. The method of claim 6 , wherein the device is a catheter.

8. The method of claim 1 , wherein the antibody is one or more of a polyclonal antibody, a monoclonal antibody, a humanized antibody, a human antibody, a veneered antibody, a diabody, a recombinant human antibody, or a chimeric antibody.

9. The method of claim 1 , wherein the antibody is a polyclonal antibody.

10. The method of claim 1 , wherein the antibody is a monoclonal antibody.

11. The method of claim 5 , wherein the antibody is one or more of a polyclonal antibody, a monoclonal antibody, a humanized antibody, a human antibody, a veneered antibody, a diabody, a recombinant human antibody, or a chimeric antibody.

12. The method of claim 5 , wherein the antibody is a polyclonal antibody.

13. The method of claim 5 , wherein the antibody is a monoclonal antibody.

14. The method of claim 1 , wherein the method comprises administering an effective amount of an antibody fragment that specifically recognizes and binds the DNABII protein.

15. The method of claim 5 , wherein the method comprises administering an effective amount of an antibody fragment that specifically recognizes and binds the DNABII protein.

16. The method of claim 1 , wherein the bacteria is selected from the group of Vibrio vulnificus, Vibrio cholera, E. coli, Legionella pneumophila, Salmonella, Shigella, Listeria, Aggregatibacter, Neisseria, S. sobrinus, S. pyogenes, S. gordonii, S. agalactiae, S. mutans, S. pneumoniae, S. gallolyticus, S. aureus, S. epidermidis, H. influenzae, Salmonella enteric serovar typhi, Aggregatibacter actinomycetemcomitans, P. gingivalis, N. gonorrhoeae, N. meningitides, P. aeruginosa, H. pylori, B. burgdorferi, Moraxella catarrhalis, Burkholderia cenocepacia, Burkholderia pseudomallei, Mycobacterium tuberculosis, Mycobacterium smegmatis, Treponema denticola, Treponema palladum, Prevotella melaninogenica, Prevotella intermedia , and Bordetella pertussis.

17. The method of claim 5 , wherein the bacteria is selected from the group of Vibrio vulnificus, Vibrio cholera, E. coli, Legionella pneumophila, Salmonella, Shigella, Listeria, Aggregatibacter, Neisseria, S. sobrinus, S. pyogenes, S. gordonii, S. agalactiae, S. mutans, S. pneumoniae, S. gallolyticus, S. aureus, S. epidermidis, H. influenzae, Salmonella enteric serovar typhi, Aggregatibacter actinomycetemcomitans, P. gingivalis, N. gonorrhoeae, N. meningitides, P. aeruginosa, H. pylori, B. burgdorferi, Moraxella catarrhalis, Burkholderia cenocepacia, Burkholderia pseudomallei, Mycobacterium tuberculosis, Mycobacterium smegmatis, Treponema denticola, Treponema palladum, Prevotella melaninogenica, Prevotella intermedia , and Bordetella pertussis.

18. The method of claim 1 or 5 , wherein the DNABII protein is a histone-like (HU) protein or an integration host factor (IHF) protein.

Assignees

• Univ Southern California
• Res Inst At Nationwide Children'S Hospital

Inventors

• Goodman Steven D
• Justice Sheryl S

Classifications

• G01N2500/04

  Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A) · CPC title

• C07K16/12 Primary

  against material from bacteria · CPC title

• G01N2500/10

  involving cells · CPC title

• C12Q1/18

  Testing for antimicrobial activity of a material · CPC title

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title